Biomarkers of Heart Failure in Myocarditis and Dilated Cardiomyopathy by DeLisa Fairweather et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
16 
Biomarkers of Heart Failure in Myocarditis  
and Dilated Cardiomyopathy 
DeLisa Fairweather, Eric D. Abston and Michael J. Coronado 
Johns Hopkins University Bloomberg School of Public Health 
USA 
1. Introduction 
There are many reviews that discuss the role of biomarkers in cardiovascular disease (CVD) 
and heart failure (Braunwald, 2008; Chen et al., 2010; Hochholzer et al., 2010), but little 
information exists regarding the presence and usefulness of biomarkers for heart failure in 
myocarditis and dilated cardiomyopathy (DCM) patients. Heart failure (HF) is the end 
consequence of many CVDs including atherosclerosis, myocardial infarction, myocarditis 
and DCM. CVD is the leading cause of morbidity and mortality in Western nations (Roger et 
al., 2011), and a growing concern worldwide (Gaddam et al., 2011). As treatments for CVD 
prolong survival, the prevalence of chronic HF has increased. It is now estimated that 5.8 
million people in the United States live with HF and over 23 million worldwide (Bui et al., 
2011). Approximately 550,000 new cases of HF are diagnosed each year, with a lifetime risk 
for developing disease of one in five (Chen et al., 2010; Krumholz et al., 1997). 
Hospitalizations for HF have also increased dramatically in the United States from 402,000 
in 1979 to 2.4 million in 2007 with the cost of treating HF patients estimated at $39 billion 
annually (Bui et al., 2011; Chen et al., 2010; Roger et al., 2011). Biomarkers have become an 
increasingly important clinical tool for assessing CVD and progression to HF. Biomarkers 
are used in early detection of sub-clinical disease, diagnosis, risk stratification, monitoring 
disease state, and to determine therapies (Hochholzer et al., 2010). Many biomarkers are also 
risk factors directly involved in the pathogenesis of disease. 
2. Heart failure 
In spite of advances in diagnosis and treatment, HF remains a growing medical problem 
associated with major hospitalization, mortality and poor prognosis. Heart failure is 
characterized by significantly reduced cardiac output resulting in an inability to meet the 
metabolic needs of the body. Most cases of HF are caused by systolic dysfunction, or 
reduced myocardial contractile function, as occurs during ischemic injury, pressure or 
volume overload and DCM. However, HF can also occur because of an inability to relax, 
expand or fill the ventricle resulting in diastolic dysfunction as observed during myocardial 
fibrosis and constrictive pericarditis (Afanasyeva et al., 2004; Kumar et al., 2005). The 
prevalence of HF is higher in men than women and sex is a major risk factor along with age, 
hypertension, left ventricular (LV) hypertrophy, valvular heart disease, obesity and diabetes 
(Bui et al., 2011; Roger et al., 2011) (Table 1). The New York Heart Association (NYHA) has 
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defined four stages of HF in patients called the NYHA classification: class I) patients who 
have no symptoms or limitations in ordinary activities; class II) patients who have no 
symptoms in rest or in mild exercise, but symptoms appear with intense activity resulting in 
slight or mild limitations; class III) patients who have a marked limitation of activity, but no 
symptoms at rest; and finally class IV) patients who have symptoms when resting and who 
are restricted to bed or chair. This classification is still widely used in clinical practice but is 
not always a reliable guide to evaluate prognosis and therapy of patients with systolic HF 
(Hebert et al., 2011). Echocardiography is the imaging method most commonly used for the 
initial clinical assessment of patients with suspected HF because it is widely available, 
versatile, non-invasive, and has a low cost (Blauwet & Cooper, 2010). However, causative 
diagnosis cannot be established in a significant number of patients with HF despite 
significant advancement in echocardiographic techniques. Cardiac magnetic resonance 
imaging (MRI) is being used with increasing frequently and often provides additional 
information to echocardiography in patients with suspected or known HF (Blauwet & 
Cooper, 2010; Karamitsos & Neubauer, 2011; Olimulder et al., 2009). Although 
echocardiography and MRI are good at defining changes in volume, they do not assess 
pressure. 
 
Nonmodifiable risk factors Potentially controllable risk factors 
Increasing age Infections 
Male gender Inflammation 
Family history Obesity 
Genetic abnormalities Alcohol 
Left ventricular hypertrophy Stress 
Myocardial infarction Air pollution 
Valvular heart disease Diabetes mellitus 
Hypersensitivity Hypertension 
 Tobacco smoking 
 Hyperlipidemia 
Table 1. Risk factors for developing heart failure. (Adapted from Bui et al., 2011 and Kumar 
et al., 2005) 
The cardiac myocyte is generally considered to be a terminally differentiated cell that has 
lost its ability to divide or regenerate. Increased mechanical load causes an increase in the 
cellular content resulting in an increase in cell size termed hypertrophy (Kumar et al., 2005). 
The extent of hypertrophy varies depending on the underlying causes (Figure 1). Volume 
overload hypertrophy is characterized by dilation and an increase in muscle mass and wall 
thickness. Cardiac hypertrophy is also accompanied by many transcriptional and 
morphologic changes including generation of myofibroblasts, collagen deposition and 
fibrosis (Figure 1). Sustained hypertrophy and/or dilation may evolve to HF. 
2.1 Myocarditis, dilated cardiomyopathy and heart failure 
Myocarditis, or inflammation of the myocardium, leads to around half of all DCM cases in 
the United States (Roger et al., 2011). DCM is the most common form of cardiomyopathy 
requiring a heart transplant (Cooper, 2009, Wexler et al., 2009). Additionally, DCM 
contributes to approximately one third of all congestive HF cases (Jameson et al., 2005). The 
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Fig. 1. Representation of the sequence of events leading to the development of heart failure. 
Viral infection or other causes of myocarditis lead to cardiac dysfunction resulting in 
increased cardiac work. Adapted from Kumar et al., 2005. 
prognosis for patients with acute myocarditis varies but depends on ejection fraction (EF), 
clinical presentation and pulmonary artery pressure (Schultz et al., 2009). The life 
expectancy after diagnosis of myocarditis is 50% at 10 years and only 50% at 4 years after 
diagnosis of DCM (Grzybowski et al., 1996; Gupta et al., 2008). Over 20% of sudden deaths 
among young adults, the military, and athletes are due to myocarditis (Gupta et al., 2008). 
Similar to coronary artery disease and HF, myocarditis and DCM occur more frequently in 
men than women (Cooper, 2009; Roger et al., 2011). The clinical presentation of acute 
myocarditis in adults is highly variable often presenting as myocardial infarction or angina 
with nonspecific symptoms. Symptoms suggesting a viral infection including fever, rash, 
myalgias, arthralgias, fatigue, and respiratory or gastrointestinal symptoms frequently occur 
several days to weeks before the onset of myocarditis (Blauwet & Cooper, 2010). 
Electrocardiogram is widely used as a screening tool for myocarditis, but only detects about 
47% of cases (Morgera et al., 1992). Echocardiography is useful for evaluating cardiac 
chamber size, wall thickness, systolic and diastolic function, and the presence of intramural 
thrombi in suspected myocarditis patients (Blauwet & Cooper, 2010). However, there is no 
specific echocardiographic feature for myocarditis, and patterns consistent with 
hypertrophy, DCM and/or ischemic heart disease can be observed in myocarditis patients. 
Cardiac MRI is an important noninvasive method to assess patients suspected to have acute 
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myocarditis. Unique features of myocarditis including myocardial edema, hyperemia, 
increased capillary permeability due to inflammation, and fibrosis can be identified using a 
combination of T1 and T2-weighted images (Blauwet & Cooper, 2010; Karamitsos & 
Neubauer, 2011). Endomyocardial biopsy is used to verify inflammation in the heart and to 
assess whether certain cell populations such as eosinophils or giant cells are present in the 
myocardium for diagnostic purposes (i.e. eosinophilic or giant cell myocarditis). Due to the 
focal nature of myocarditis and the fact that foci are frequently located in the 
peri/myocardium, endomyocardial biopsies often miss inflammation and so often do not 
aid in diagnosis (Maisch, 1994; Olimulder et al., 2009). Although the complication rate is 
low, patients are at a risk of death from the procedure. 
3. Biomarkers in heart failure 
Biomarkers are frequently used in cardiovascular medicine where they provide valuable 
information regarding diagnosis, treatment, identification of individuals at risk for HF, and 
potentially the pathogenesis of disease. For a biomarker to be clinically useful it should 
fulfill several criteria: 1) biomarker levels should be able to be accurately assessed using 
widely available and cost-efficient methods, 2) biomarkers should provide additional 
information from the tests already conducted such as MRI, and 3) biomarker information 
should aid in medical decision making (Braunwald, 2008; Morrow & de Lemos, 2007). A 
growing list of enzymes, hormones, markers of cardiac stress or necrosis, cytokines and 
other biological agents have been examined as possible biomarkers for HF (Table 2). 
Although biomarkers are discussed in this review by category (e.g. those associated with 
cardiac damage or inflammation), in reality many of these biomarkers interact or are 
associated with one another suggesting that combinations of biomarkers are likely to 
provide the best assessment of HF risk. This review will focus on HF biomarkers from Table 
2 that have been studied in myocarditis/ DCM patients or experimental models. 
3.1 Biomarkers of cardiovascular injury or stress 
Myocyte injury can occur from many causes including infections, oxidative stress, 
inflammation or severe ischemia (Brauanwald, 2008). Cardiac myosin is typically not used 
as a biomarker for HF because it is rapidly cleared from the circulation. Cardiac troponin I 
and T are current standard biomarkers used to diagnose acute myocardial infarction and to 
stratify patient risk in acute coronary syndromes (ACS) because of their long half-life in the 
circulation (Hochholzer et al., 2010). B-type natriuretic peptide (BNP) and N-terminal pro-
brain natriuretic peptide (NT-pro-BNP) are important indicators of cardiovascular stress 
having the advantage of being able to distinguish acute from chronic HF. Recently ST2 has 
emerged as another biomarker of cardiac damage that has prognostic ability in patients 
suspected of HF. 
3.1.1 Troponins I and T 
The cardiac troponins are proteins located in myocytes that are responsible for regulating 
cardiac muscle contraction. Cardiac troponin is composed of three subunits that are 
products of different genes- troponin C, troponin I and troponin T. Compared to myosin 
and actin, troponins are present at low levels in the heart. However, both troponin I and T 
are ideally suited to detect myocardial damage because they are expressed as cardiac-
specific isoforms (Agewall et al., 2011). Elevated sera troponins are associated with 
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Biomarker 
Myocyte inury 
Cardiac-specific troponins I and T 
Myosin light-chain kinase I 
Creatine kinase MB fraction 
Myocyte stress 
Brain natiuretic peptide 
N-terminal pro-brain natriuretic peptide 
ST2/ interleukin-33 
Inflammation 
C-reactive protein 
Tumor necrosis factor 
Fas (APO-1) 
Interleukins 1, 6, 18 
Galectin-3 
Oxidative stress 
Oxidized low-density lipoproteins 
Myeloperoxidase 
Urinary and plasma isoprostanes 
Neurohormones 
Norepinephrine 
Renin 
Angiotensin II 
Aldosterone 
Endothelin 
Extracellular-matrix remodeling 
Matrix metalloproteinases 
Tissue inhibitors of metalloproteinases 
Collagen propeptides 
Table 2. Biomarkers in heart failure. (Adapted from Braunwald, 2008) 
myocardial ischemia and necrosis and have been found to be excellent diagnostic and 
prognostic biomarkers for thrombotic ACS. But many cardiac conditions can lead to 
elevated troponins in addition to ACS including myocarditis, DCM and HF (Table 3). With 
new high-sensitivity detection methods for troponins, very minor changes in cardiac 
damage can be detected. Although troponins released to the circulation do not identify the 
type of heart damage, their levels may indicate the severity of damage (Figure 2) (Miller et 
al., 2007). A number of studies have been conducted examining troponin release during 
myocarditis, DCM or heart failure in patients (Smith et al., 1997; Brandt et al., 2001; Imazio 
et al., 2008; Miller et al., 2007; Peacock et al., 2008). Troponin I and T have also been found to 
predict the severity of myocarditis and the short-term prognosis in children with acute and 
fulminant myocarditis and DCM (Soongswang et al., 2002; Al-Biltagi et al., 2010). Overall, 
troponin levels were found to increase in relation to the severity of myocardial inflammation 
or ventricular wall stress caused by remodeling (Agewall et al., 2011; Miller et al., 2007). 
DCM patients with elevated serum troponin I levels were more dilated and had a worse 
outcome that troponin I-negative patients (Miettinen et al., 2008). Additionally, acute 
decompensated heart failure patients who were positive for troponin had a lower EF and 
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higher in-hospital mortality, independent from other predictive values, than those who 
were negative for troponin (Peacock et al., 2008). Troponin T was found to be an important 
independent variable that predicted increased risk of death in patients with chronic HF 
(Latini et al., 2007). These findings demonstrate that troponin measurement is an important 
tool in early risk assessment of myocarditis/ DCM patients. 
 
Condition 
Acute coronary syndrome 
Myocarditis 
Pericarditis 
Endocarditis 
Dilated cardiomyopathy 
Acute heart failure 
Pulmonary embolism 
Stroke 
Sepsis 
Acute aortic dissection 
Tachyarrhythmias 
Cardiac contusion 
Tako-tsubo cardiomyopathy 
Strenuous exercise e.g. marathon runners 
Sympathomimetic drugs 
Chemotherapy 
Table 3. Cardiac conditions that can result in acutely elevated troponins. (Adapted from 
Agewall et al., 2011) 
Interestingly, autoantibodies against circulating troponin I have been found in patients with 
ACS and acute myocardial infarction (Eriksson et al., 2005; Leuschner et al., 2008; 
Shmilovich et al., 2007). These autoantibodies were discovered because they interfered with 
troponin detection assays (Eriksson et al., 2005). This discovery led to the realization that 
autoantibodies against troponin I were also present in the sera of patients with DCM and 
heart failure (Miettinen et al., 2008; Shmilovich et al., 2007). One study of DCM patients 
found that troponin I, but not troponin I autoantibodies, were associated with dilation and 
poor outcome (Miettinen et al., 2008). In another study a significant number of DCM 
patients had autoantibodies against troponin I, but the autoantibodies were not found to 
bind to cardiac myocytes or activate Ca2+ currents (Shmilovich et al., 2007). Myocardial 
infarction patients with elevated troponin I autoantibodies had poor recovery of LV EF 
suggesting that troponin autoantibodies affect heart function (Leuschner et al., 2008). 
Further evidence that troponin autoantibodies may directly affect heart function comes from 
animal studies. PD-1 receptor deficient mice were found to develop severe DCM with high 
levels of autoantibodies against tropoinin I (Kaya et al., 2010; Nishimura et al., 2001). These 
troponin I autoantibodies were found to bind to heart tissue and to induce Ca2+ influx in 
cardiac myocytes. Inoculation of mice with recombinant troponin I with complete Freund’s 
adjuvant was found to induce severe myocarditis and increased proinflammatory cytokines 
that progressed to fibrosis, DCM and heart failure (Goser et al., 2006; Kaya et al., 2008; 2010). 
However, this inflammatory response was only observed for troponin I but not troponin T 
inoculation. More research is needed to better understand the relationship of circulating 
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troponin I and its autoantibodies in the progression of myocarditis to DCM and heart 
failure. 
 
 
Fig. 2. Relationship between serum troponin levels and the severity of cardiac damage 
caused by myocarditis, heart failure or myocardial infarction. Adapted from Agewall et al., 
2011. 
3.1.2 BNP and NT-pro-BNP 
In contrast to cardiac myosin or troponins that are released due to cell wall compromise, 
BNP is synthesized in healthy cardiac myocytes from its precursor NT-pro-BNP 
(Braunwald, 2008; Chen et al., 2010). The prohormone BNP is only released to the circulation 
when the ventricles become dilated, hypertrophic or during other conditions that induce 
wall distension and stretching, and by neurohormonal activation (Table 4). Prohormone 
BNP is cleaved by an endoprotease, corin, in the circulation into two polypeptides: the 
inactive NT-pro-BNP and the bioactive BNP. BNP causes arterial vasodilation, natriuresis 
and diureses while reducing the renin angiotensin system and adrenergic response 
(Braunwald, 2008; Palazzuoli et al., 2011). Elevated plasma BNP levels occur during 
hypertrophic cardiomyopathy, diastolic dysfunction and LV hypertrophy, and have been 
shown to be directly proportional to NYHA class and inversely related to cardiac output 
(Silver et al., 2004). Although few studies specifically address the topic, BNP has been found 
to be elevated in the serum of patients with myocarditis or DCM and in animal models of 
myocarditis (Grabowski et al., 2004; Miller et al., 2007; Ogawa et al., 2008; Talvani et al., 
2004; Tanaka et al., 2011). Plasma BNP levels are also elevated in patients with acute 
myocardial infarction and this relationship persists into the late phases of cardiac 
remodeling (Hirayama et al., 2005). Many studies have linked higher levels of circulating 
BNP with heart failure diagnosis and worse outcome (Miller et al., 2007; Palazzuoli et al., 
2011). BNP levels are a better predictor of death than norepinephrine or endothelin-1 
(Braunwald, 2008). Several studies have found that NT-pro-BNP was better than BNP for 
predicting death or re-hospitalization for heart failure, probably due to the longer half-life of 
NT-pro-BNP in sera (Masson et al., 2006; Omland et al., 2007). However, BNP is a better 
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predictor than NT-pro-BNP of worse outcome in ACS (Palazzuoli et al., 2011). Natriuretic 
peptides were also found to be useful in screening asymptomatic subjects at risk of 
developing HF such as those with hypertension, diabetes and coronary artery disease 
(Braunwald, 2008). Noncardiac conditions that increase plasma BNP levels such as age, race, 
obesity and renal dysfunction should be taken into consideration when using this biomarker 
(Table 4). Overall, BNP and NT-pro-BNP are biomarkers with a high sensitivity and 
specificity in predicting HF in a number of conditions including myocarditis and DCM. 
 
Cardiac condition Noncardiac condition 
Systolic dysfunction  Acute pulmonary embolism 
Diastolic dysfunction Pulmonary hypertension 
Myocarditis Anemia 
Pericarditis Septic shock 
Myocardial fibrosis Hyperthyroidism 
Dilated cardiomyopathy Cor pulmonale 
Heart failure Renal failure 
Valvular heart disease  
Coronary artery disease  
Hypertension  
Atrial fibrillation  
Table 4. Conditions that increase plasma natriuretic peptide levels. (Adapted from 
Braunwald, 2008 and Palazzuoli et al., 2011) 
3.1.3 Soluble ST2 
Soluble ST2 (sST2), an interleukin (IL)-1 receptor (R) (IL-1R) family member, is basally 
expressed by cardiomyocytes and upregulated in the heart by mechanical strain and IL-1 
(Weinberg et al., 2002). The ST2 gene is known to encode at least 3 isoforms of ST2 by 
alternative splicing: ST2L, a transmembrane receptor; sST2, a secreted soluble form of ST2 
that can serve as a decoy receptor for the ST2 ligand, IL-33; and ST2V, a variant of ST2 found 
in the gut of humans (Miller & Liew, 2011). ST2L is a member of the Toll-like receptor 
(TLR)/IL-1R superfamily that share a common structure with an extracellular domain of 
three linked immunglobulin-like motifs, a transmembrane segment and a cytoplasmic Toll-
interleukin-1 receptor (TIR) domain. ST2L forms a complex with IL-1R accessory protein (IL-
1RAcP) that is required for IL-33 signaling (Ali et al., 2007). IL-33 signaling recruits the 
adaptor protein MyD88 to the TIR domain leading to activation of the transcription factors 
NF-B and AP-1 and production of inflammatory mediators including proinflammatory 
tumor necrosis factor (TNF), IL-1, IL-6, and the T helper (Th)2-associated cytokines IL-5, IL-
13 and IL-10 (Liew et al., 2010; Miller & Liew, 2011). Both ST2L and sST2 are induced in 
cardiomyocytes by biomechanical strain (Weinberg et al., 2002). Elevated levels of sST2 in 
the sera are associated with poor prognosis in patients with acute myocardial infarction or 
chronic heart failure where sST2 levels correlate positively with creatine kinase and 
negatively with EF (Weinberg et al., 2002; 2003). In patients with severe chronic NYHA class 
III or IV heart failure, the change in sST2 levels was an independent predictor of subsequent 
mortality or transplantation (Weinberg et al., 2003). IL-33 is expressed largely within 
fibroblasts in the heart and is thought to be released from necrotic cells due to tissue damage 
caused by direct damage or infection (Liew et al., 2010). IL-33 has been shown to be 
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cardioprotective using animal models where recombinant (r)IL-33 treatment reduced 
hypertrophy and fibrosis following pressure overload induced by transverse aortic 
constriction (TAC) (Sanada et al., 2007). This effect was reversed by treating mice with sST2 
prior to TAC, providing evidence that sST2 functions as a decoy receptor for IL-33. 
Additionally, rIL-33 treatment was found to decrease atherosclerosis in ApoE deficient mice 
fed a high fat diet by skewing the immune response from a Th1 to a Th2 response (Miller et 
al., 2008). 
Currently there are no reports on the role of sST2 or IL-33 in the development of myocarditis 
or DCM even though sST2 is known to be a good biomarker predicting heart failure. Our 
laboratory is investigating the role of sST2/IL-33 signaling in an autoimmune model of 
coxsackievirus B3 (CVB3) myocarditis and DCM in mice. We found that IL-33 mRNA was 
upregulated in the heart during acute CVB3 myocarditis and chronic DCM (Figure 3A,B). 
Additionally, sST2 levels were elevated in the sera during acute CVB3 myocarditis in mice 
(Figure 3C) and correlated with poor heart function as assessed by echocardiography (not 
shown) or pressure-volume relationships (Figure 4). Serum sST2 is a good marker of disease 
because it could not be detected in the sera of undiseased mice (Figure 3C). Our findings of 
elevated sST2 levels in the sera of mice with CVB3 myocarditis and its relation to poor heart 
function suggest that sST2 may serve as a useful biomarker to predict progression to HF in 
myocarditis and DCM patients. 
 
 
Fig. 3. IL-33 and sST2 are increased during autoimmune CVB3 myocarditis in mice. Male 
BALB/c mice were infected intraperitoneally with heart-passaged coxsackievirus B3 (CVB3) 
containing infectious CVB3 (103 plaque forming units) and heart proteins on day 0 and 
myocarditis examined at day 10 post infection (pi) and dilated cardiomyopathy (DCM) at 
day 90 pi. Saline inoculated age-matched mice were used as controls. Interleukin (IL)-33 
mRNA was assessed by quantitative RT-PCR in the heart at day 10 (A) and 90 (B) pi and 
normalized to hypoxanthine phosphoribosyltransferase (HPRT) levels. sST2 levels were 
assessed in the sera of mice during acute myocarditis at day 10 pi by ELISA (C). Data are 
expressed as mean relative gene expression (RGE) ±standard error of the mean (SEM) in 7 to 
10 mice per group. *P < 0.05; ***P < 0.001. 
3.2 Biomarkers of inflammation 
Inflammation is important in the pathogenesis of many of the conditions that lead to HF. 
Traditionally, inflammatory biomarkers have been considered to be risk markers rather than 
risk factors because their role in disease pathogenesis is not always clear (Rao et al., 2006). 
Many inflammatory biomarkers found in the circulation, such as C-reactive protein (CRP), 
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Fig. 4. Poor heart function in TRIF deficient mice is associated with elevated sST2 during 
acute CVB3 myocarditis. Male C57BL/6 (BL/6) or TRIF deficient (TRIF-/-) mice were 
infected intraperitoneally with heart-passaged coxsackievirus B3 (CVB3) containing 
infectious CVB3 (103 plaque forming units) and heart proteins on day 0 and myocarditis 
examined at day 10 post infection (pi) using end systolic pressure-volume relationships 
(ESPVR). Ees, a measure of LV end systolic stiffness/elastance, was 7.1 in BL/6 and 5.1 in 
TRIF-/- mice (P = 0.04) while V0, the X-intercept of the ESPVR, was -5.4 in BL/6 and 26.8 in 
TRIF-/- mice (P = 0.0001). End diastolic volume (EDV) was 24±1.2 in BL/6 and 33±3.3 in 
TRIF-/- mice (P < 0.01). Thus, elevated sST2 in the sera of TRIF-/- mice (not shown) was 
associated with dilation and heart failure in TRIF deficient mice in an autoimmune model of 
CVB3 myocarditis. 
IL-6 and serum amyloid A protein (SAA), are part of the acute phase response arising in the 
liver and although they are strongly associated with disease they may simply infer the 
presence of an inflammatory state. In clinical studies inflammatory mediators have been 
found to predict progression to HF similar to injury biomarkers and/or neurohormones 
(Table 2) (Mann, 2005). Inflammatory biomarkers have been shown in animal studies and 
the clinical setting to increase LV dysfunction, increase edema, and induce endothelial 
dysfunction and cardiomyocyte apoptosis, as well as other deleterious effects (Table 5). 
A recent long-term study of myocarditis patients revealed that inflammation was the best 
predictor for the progression to HF following acute myocarditis (Kindermann et al., 2008). 
Viruses like CVB3, adenovirus, parvovirus B19 and hepatitis C virus are often detected in 
patient myocardial biopsies (Cooper, 2009; Gupta et al., 2008). Antiviral treatments such as 
interferon- reduce inflammation and HF in animal models and patients, implying that viral 
infections are an important cause of myocarditis cases that lead to HF (Kuhl et al., 2003; 
Wang et al., 2007). Inflammation appears to be etiologically linked with the development of 
HF, not only because heart failure is a consequence of inflammatory CVDs but because 
patients with chronic HF that have elevated levels of inflammatory mediators have a worse 
prognosis (Robinson et al., 2011). Evidence exists that both cellular and auto/antibody-
mediated damage contribute to the progression to DCM and HF following myocarditis 
(Cooper, 2009; Fairweather et al., 2008; Kallwellis-Opara et al., 2007). Similar to 
atherosclerosis, acute myocardial inflammation is associated with an elevated Th1 response 
in males (Daniels et al., 2008; Frisancho-Kiss et al., 2007; Huber and Pfaeffle, 1994; Nishikubo 
et al., 2007). A Th17 response has been shown to increase fibrosis leading to DCM in the 
experimental autoimmune myocarditis (EAM) model in mice (Baldeviano et al., 2010). 
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Interestingly, Th2 responses have also been implicated in the pathogenesis of myocarditis 
leading to HF (Afanasyeva et al., 2001; Fairweather et al., 2004a; 2004b). IFN- deficient mice, 
which have elevated IL-4 levels and a Th2 response, progress to severe DCM and HF 
following CVB3 myocarditis (Fairweather et al., 2004a). 
 
Deleterious effects 
Known 
Left ventricular dysfunction 
Pulmonary edema 
Cardiomyopathy 
Inflammation 
Left ventricular remodeling 
Endothelial dysfunction 
Inducible nitric oxide synthase activation 
Decreased skeletal-muscle blood flow 
Anorexia and cachexia 
Potential 
Receptor uncoupling from adenylate cyclase 
Activation of the fetal-gene program 
Apoptosis of cardiac myocytes 
Table 5. Deleterious effects of inflammatory biomarkers on acute and chronic heart failure. 
(Adapted from Anker & von Haehling, 2004; Braunwald, 2008; Mann, 2005) 
3.2.1 C-reactive protein 
Interest in the study of inflammatory mediators in patients with HF began in 1954 when an 
assay for CRP was first developed (Braunwald, 2008). CRP is an acute phase protein 
synthesized in the liver in response to IL-6 and released to the circulation during 
inflammation (Pepys & Hirschfield, 2003). Its levels are synergistically increased by IL-1. In 
phagocytes CRP has been shown to bind Fc receptor I and II and to function in the 
clearance of apoptotic and necrotic cells (Devaraj et al., 2009; Rhodes et al., 2011). In 1956 a 
study was published showing that CRP was detectible in the sera of 30 out of 40 patients 
with chronic HF, and that elevated CRP levels were associated with more severe disease 
(Braunwald, 2008; Elster et al., 1956). Since then many studies have shown that CRP 
independently predicts adverse outcomes in patients with acute or chronic HF (Braunwald, 
2008; Osman et al., 2006). Higher levels of CRP are associated with more severe HF and 
independently associated with morbidity and mortality (Anand et al., 2005). Additionally, 
elevated CRP levels identified asymptomatic elderly individuals who were at a high risk of 
developing HF in the future (Vasan et al., 2003). The main problem with CRP as a biomarker 
is that it lacks specificity for CVD. That is, CRP levels are elevated in the sera during most 
conditions that increase inflammation such as acute or chronic infection, cigarette smoking, 
ACS and some autoimmune diseases (Pepys & Hirschfield, 2003; Perez-De-Lis et al., 2010; 
Rhodes et al., 2011). There is increasing evidence that CRP may be able to exert direct 
proinflammatory effects on the heart by increasing matrix metalloproteinase-1 (MMP)-1 and 
IL-8 in endothelial cells and by increasing CD11b and CC-chemokine receptor 2 (CRR2) in 
monocytes, for example (Table 6) (Devaraj et al., 2009; Osman et al., 2006; Venugopal et al., 
2005). 
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Endothelial cells Monocyte-macrophages Smooth muscle cells 
Increased VCAM, ICAM-1, 
E-selectin, MCP-1 and 
monocyte adhesion 
Increased tissue factor 
Increased AT-1 and 
VSMC migration and 
proliferation 
Increased PAI-1, IL-8, 
CD40/CD40L, MMP-1, ET-1 
and M-CSF 
Increased superoxide and 
myeloperoxidase 
Increased neointimal 
formation in vivo 
Decreased tPA 
Increased proinflammatory 
cytokines (e.g. TNF) and 
decreased IL-10 
Increased iNOS 
Decreased prostacyclin Increased CD11b and CCR2 Increased ROS 
Increased superoxide and 
iNOS 
Promoted oxLDL uptake and 
decreases cholesterol efflux 
Increased tissue factor 
Promoted endothelial 
dysfunction in vivo 
Increased MMPs and HMGB1  
Impaired EPC number and 
function in vitro 
Increased M-CSF and 
proliferation 
 
Table 6. Inflammatory effects of C-reactive protein. (Adapted from Devaraj et al., 2009) 
Abbreviations: AT, angiotensin receptor; CCR2, CC-chemokine receptor-2; CD40L, CD40 
ligand; EPC, endothelial progenitor cell; ET, endothelin; HMGB1, high-mobility group 
protein B1; ICAM, intercellular adhesion molecule; IL, interleukin; iNOS, inducible nitric 
oxide synthase; MCP, monocyte chemotactic protein; M-CSF, macrophage colony-
stimulating factor; MMP, matrix metalloproteinase; oxLDL, oxidative low-density 
lipoprotein; PAI, plasminogen activator inhibitor; ROS, reactive oxygen species; TNF, tumor 
necrosis factor; tPA, tissue plasminogen activator; VCAM, vascular cell adhesion molecule; 
VSMC, vascular smooth muscle cell. 
Although many studies have examined the relationship between serum CRP levels and HF, 
few studies have examined CRP levels in myocarditis patients. In one study, 31 patients 
with clinical and histological evidence of lymphocytic myocarditis were found to have 
elevated plasma CRP levels that correlated positively with the NYHA functional class 
(Kaneko et al., 2000; Osman et al., 2006). Five of these patients who died of HF during the 
study had significantly higher levels of CRP, suggesting that CRP measurement may be a 
useful tool for determining prognosis in myocarditis patients. A separate study found that 
80% of patients with clozapine-induced myocarditis (an antipsychotic drug used to treat 
schizophrenic symptoms) had elevated levels of CRP compared to a control group 
(Ronaldson et al., 2010). Several studies have examined CRP levels in idiopathic/ non-
ischemic DCM patients where CRP levels have been found to independently predict disease 
outcome (Ishikawa et al., 2006; Kaneko et al., 1999; Senes et al., 2008). CRP levels increased 
with the severity of symptoms and the level of systolic impairment in DCM patients, while 
ongoing statin treatment was found to decrease CRP levels (De Gennaro et al., 2008). 
Interestingly, CRP has been found to co-express with TNF, macrophages and complement in 
the myocardium of DCM patients suggesting that CRP may play a role in the pathogenesis 
of disease (Satoh et al., 2005; Zimmermann et al., 2009). One of the obstacles to 
understanding the role of CRP in myocarditis and DCM is that mouse CRP appears only in 
trace amounts during the acute phase response (Pepys & Hirschfield, 2003). Instead of CRP 
mice upregulate serum amyloid P component (SAP), which is a non-acute phase protein in 
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humans. Thus, CRP deficient or transgenic mice may provide only limited information on 
the role of CRP in HF promotion. 
3.2.2 Cytokines: TNF, IL-1 and IL-18 
The inability of hemodynamic factors to fully explain HF cases led to the hypothesis that 
cytokines released from cardiac tissue and/or inflammatory cells also contribute to disease 
progression. According to the “cytokine hypothesis”, HF develops because cytokine 
cascades that are activated following myocardial injury or stress exert deleterious effects on 
heart function (Table 5) (Anker & von Haehling, 2004; Braunwald, 2008; Seta et al., 1996). 
Cytokines can induce hemodynamic abnormalities and/or direct toxic effects on the heart. 
Since the original report in 1990 by Levine et al. there have been many studies showing that 
an increase in circulating TNF levels directly relates to a patient’s NYHA classification and 
predicts patient mortality (Anker & von Haehling, 2004; Mann, 2005; Seta et al., 1996; Vasan 
et al., 2003). Similar relationships between IL-1, IL-6 or IL-18 and HF have been found 
(Anker & von Haehling, 2004; Hedayat et al., 2010; Jefferis et al., 2011; Vasan et al., 2003). 
Cardiac myocyte hypertrophy, contractile dysfunction, cardiac myocyte apoptosis and 
extracellular matrix (ECM) remodeling contribute critically to the progression from cardiac 
injury to HF (Hedayat et al., 2010). 
More than any other category of biomarker (Table 2), the role of cytokines in the 
pathogenesis of myocarditis and DCM has been studied by researchers (Fairweather & Rose, 
2005; Hedayat et al., 2010). TNF, IL-1 and IL-18 have all been shown to play a role in 
myocarditis by inducing myocyte hypertrophy, contractile dysfunction, myocyte apoptosis 
and contributing to ECM remodeling, a step critical in the progression from myocarditis to 
DCM (Cain et al., 1999; Fairweather et al., 2004a; 2004b; Hedayat et al., 2010). In one study, 
TNF mRNA expression was found to be elevated more often in myocarditis patients when 
viral genomes were also detected, and greater mRNA levels of TNF and its receptor TNFRI 
correlated with impaired cardiac function (Calabrese et al., 2004). In a mouse model of CVB3 
myocarditis, TNF was found to increase CD1d expression on lymphocytes resulting in 
increased inflammation in males (Huber, 2010). However, viral replication and acute CVB3 
myocarditis was not altered in TNFRI deficient mice (Fairweather et al., 2005). Out of the 13 
or so TLRs that have been described so far in humans and mice, TLR4 is unique in its ability 
to work with the inflammasome to produce bioactive IL-1 and IL-18 in the heart 
(Fairweather et al., 2003; Vallejo, 2011). TLR2 and TLR4 signaling increase TNF levels, and 
TLR2 can act with TLR4 to increase IL-1 levels (Vallejo, 2011). TLR4 mRNA expression has 
been found to be higher in patients with myocarditis than controls, and to correlate with 
viral RNA levels in the heart (Satoh et al., 2003). Myocarditis patients with active viral 
replication had higher levels of TLR4 that was associated with lower systolic function. In a 
mouse model of CVB3 myocarditis, our laboratory found that TLR4 deficient mice develop 
reduced acute inflammation and lower IL-1 and IL-18 levels in the heart (Fairweather et al., 
2003). The importance of TLR4 signaling in a strictly autoimmune model of myocarditis was 
demonstrated by Nishikubo et al. where TLR4 signaling was found to be necessary to 
mount a Th1-type immune response (Nishikubo et al., 2007). We have shown that TLR4 is 
upregulated on macrophages and mast cells during the innate immune response to CVB3 
and during acute CVB3 myocarditis and this response results in increased inflammation and 
progression to DCM and HF in males compared to females (Frisancho-Kiss et al., 2007; 2009; 
Onyimba et al., 2011). A Th1 response in male mice was found to be due to TLR4-derived IL-
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18, which was originally named IFN--inducing factor, rather than to a classical IL-
12/STAT4-induced Th1 response (Frisancho-Kiss et al., 2006). We were surprised to find 
that TLR4 was expressed on alternatively activated M2 macrophages (induced by Th2 
cytokines) rather than classically activated M1 macrophages (induced by Th1 cytokines) 
within the heart during acute CVB3 myocarditis (Fairweather & Cihakova 2009; Frisancho-
Kiss et al., 2009). These CD11b+GR1+F4/80+ M2 macrophages expressed TLR4 and IL-1 
(Frisancho-Kiss et al., 2009). We, and others, have shown that IL-1 is particularly important 
in the cardiac remodeling that leads to fibrosis, DCM and HF following acute myocarditis 
(Blyszczuk et al., 2009; Cihakova et al., 2008 Fairweather et al., 2004a; 2006). Further work is 
needed to better understand the role of innate TLRs and cytokine production/regulation in 
the heart in order to determine whether anti-cytokine therapies will be effective once disease 
has progressed to the point of being clinically apparent (Mann, 2005). Another area that 
needs to be addressed in animal models is the relationship between sera levels of 
proinflammatory cytokines and the stage of disease (i.e. acute myocarditis vs. DCM) and 
whether increases in sera levels of cytokines predict HF. 
3.3 Biomarkers of extracellular matrix remodeling 
Remodeling of the ventricles plays an important role in the progression to HF (Braunwald, 
2008). The extracellular matrix provides a framework for cardiac myocytes, mediates cell 
adhesion and cell-to-cell communication, mediates diastolic stiffness, promotes cell survival 
or apoptosis, and is a reservoir for growth factors and cytokines (Liu et al., 2006). Release of 
cytokines and growth factors at the site of tissue injury and by inflammatory cells induces 
fibroblast proliferation and deposition of collagen, which is the primary component of the 
ECM resulting in scar tissue (Figure 5). Profibrotic cytokines, such as TNF and IL-1 and 
growth factors, like transforming growth factor (TGF)1 and fibroblast growth factor (FGF), 
induce collagen production from fibroblasts. Normally a balance exists between matrix 
metalloproteinases (MMPs) that proteolytically degrade fibrillar collagen and tissue 
inhibitors of MMPs (TIMPs). However, during inflammatory CVDs an imbalance in MMPs 
and TIMPs contributes to collagen deposition, ventricular dilatation and remodeling 
resulting in DCM and HF. The activity of MMPs has been shown to be increased in the 
progression to HF (Bradham et al., 2002; Tyagi et al., 1996). Serum MMP9, for example, has 
been found to predict CVD mortality better than other traditional prognostic markers such 
as cholesterol, CRP or IL-6 (Blankenberg et al., 2003; Liu et al., 2006).  
The progression from myocarditis to fibrosis, DCM and HF has been well documented in 
clinical studies and animal models (Fairweather et al., 2004a; Kania et al., 2009; Looi et al., 
2010). Studies in our laboratory have revealed a two-stage process where increases in 
profibrotic mediators during acute CVB3 myocarditis, which occurs from day 8 to 12 post 
infection, result in a gradual remodeling that progresses to fibrosis and DCM by day 35 post 
infection (Figure 5) (Fairweather et al., 2004a; 2006; Fairweather & Rose, 2007). In both 
animal and human studies of DCM, genes associated with extracellular matrix remodeling 
and fibrosis are upregulated with disease (Piro et al., 2010; Yung et al., 2004). TNF, IL-1, IL-
4, IL-6, IL-17 and TGF- have all been found to initiate remodeling (Baldeviano et al., 2010; 
Blyszczuk et al., 2009; Fairweather et al., 2004a; Heymans, 2006; Kania et al., 2009). There are 
many MMPs, but only 4 known TIMPS. MMPs are upregulated in the heart during EAM 
and during viral myocarditis (Marchant & McManus, 2009; Tang et al., 2007; Westermann et 
al., 2010). Individual MMPs and TIMPs have been found to differ in their effects on 
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myocarditis in rodents (Liu et al., 2006; Marchant & McManus, 2009; Westermann et al., 
2010). For example, MMP9 deficient mice had increased CVB3 replication and inflammation, 
and worse heart function than wild type controls, indicating that MMP9 protects the heart 
from CVB3 myocarditis (Cheung et al., 2008). In contrast, TIMP-1 deficient mice were 
protected from CVB3 myocarditis indicating that TIMP-1 increases disease (Crocker et al., 
2007). Although a number of studies have examined the role of MMPs and TIMPs in 
myocarditis, the relationship between serum levels of these factors and the progression to 
DCM and HF is not yet clear from animal models. 
 
 
Fig. 5. Development of fibrosis and DCM following acute myocarditis. Macrophages and 
lymphocytes present within the myocardium during acute myocarditis release profibrotic 
cytokines such as tumor necrosis factor (TNF), interleukin (IL)-1, IL-4 and IL-13 that 
activate fibroblasts to release collagen. Inflammation additionally stimulates the release of 
growth factors like platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) 
and transforming growth factor (TGF)-1, which act with cytokines to increase collagen 
production. Cytokines and growth factors released from inflammatory cells and cardiac 
tissues contribute to pathology. Normally a balance exists between matrix 
metalloproteinases (MMPs) that proteolytically degrade fibrillar collagen and tissue 
inhibitors of MMPs (TIMPs). However, during acute myocarditis an imbalance in MMPs 
and TIMPs contributes to collagen deposition, ventricular dilatation and remodeling 
resulting in dilated cardiomyopathy (DCM) and heart failure. 
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3.4 Thrombosis biomarkers 
Atherosclerosis is a major initiator of thrombi formation that can restrict blood flow and 
lead to a heart attack (Carter, 2005). Cardiac mural thrombi can arise from a myocardial 
infarction, infection, inflammation (e.g. myocarditis) or rheumatic heart disease, for 
example. Although research has led to a clear understanding of conditions that induce 
thrombosis, the precise pathology leading to disease remains unclear. Thrombi can develop 
anywhere in the cardiovascular system like in the ventricular or atrial chambers, arteries, 
veins or capillaries. The size and shape of individual thrombi vary depending on the 
circumstances leading to their development. They often are found at sites of endothelial 
injury. Once thrombi have formed (acute) they may accumulate more platelets and fibrin 
and grow larger, or dislodge and travel to other sites, or be removed by fibrinolytic activity, 
and finally they can attract inflammation, undergo remodeling with deposition of collagen 
and be reincorporated into the vessel or myocardium (Kumar et al., 2005) (Figure 6).  
 
 
Fig. 6. Mural thrombi develop during acute CVB3 autoimmune myocarditis in mice and 
reincorporate into the myocardium. Male BALB/c mice were infected intraperitoneally with 
heart-passaged coxsackievirus B3 (CVB3) containing infectious CVB3 (103 plaque forming 
units) and heart proteins on day 0 and thrombus formation examined at day 10 post 
infection (pi) during acute myocarditis (A) or during chronic myocarditis/DCM at day 35 pi 
(B). H&E staining shows ventricular mural thrombus at day 10 pi (magnification, x100) (A). 
Masson’s trichrome stains bright blue revealing collagen composition of mural integrated 
ventricular thrombus at day 35 pi (magnification, x100) (B).  
Damage of cardiac tissue by viruses and inflammation is known to release tissue factor (TF), 
the main initiator of the coagulation cascade that results in the formation of fibrin and 
thrombotic clots (Mackman, 2009). Mural thrombi are known to occur in viral models of 
myocarditis in mice as well as in myocarditis patients (Antoniak et al., 2008; Kojima et al., 
1988; Kuh & Seo, 2005). Furthermore, DCM patients demonstrate a high frequency of LV 
thrombi and prothrombotic characteristics like high levels of circulating fibrinogen and 
antithrombin III (Abdo et al., 2010). Many studies have shown that TF can increase 
inflammation by stimulating release of IL-6, a cytokine that along with TNF and IL-1 has 
been strongly associated with poor CVD outcome (Braunwald, 2008; Carter, 2005; Mackman, 
2009; Rao et al., 2006). Complement components also contribute to thrombosis by depositing 
at sites of tissue damage and by activating platelets (Fairweather et al., 2006; Peerschke et al., 
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2010). Eosinophils are potent inducers of ECM remodeling, releasing many profibrotic 
factors including IL-1, IL-6, TGF-, MMPs, and TIMPs (Shamri et al., 2011). Additionally, 
eosinophils release potent prothrombotic agents such as major basic protein, eosinophilic 
cationic protein, and eosinophil peroxidase, as well as directly and/or indirectly activating 
TF (Ames et al., 2010). Eosinophilia, fibrosis and thrombosis are characteristics of 
eosinophilic cardiovascular diseases like Churg Strauss syndrome, a form of vasculitis, 
hypereosinophilic syndrome, eosinophilic myocarditis and giant cell myocarditis (Ames et 
al., 2010; Cooper, 2000; 2009; Kleinfeldt et al., 2010; Rezaizadeh et al., 2010). Circulating 
biomarkers that may indicate a hypercoagulable state include complement C3, C4, IL-6, 
fibrinogen or antithrombin III (Abdo et al., 2010). Complement components were recently 
found to be elevated in the sera of mycarditis and DCM patients (Cooper et al., 2010). We 
have found that complement receptor 1 deficient mice, a receptor that regulates C3 levels, 
develop severe CVB3 myocarditis, dilation and HF with elevated levels of IL-1 in the heart 
and fibrosis (Fairweather et al., 2006). Overactivation of the terminal complement complex 
(C5b-9) has been shown to contribute to the progression of myocarditis to DCM in mice, 
indicating the importance of complement in regulating disease (Zwaka et al., 2002). Overall, 
these findings suggest that biomarkers of coagulation and/or thrombosis are likely to be 
important indicators of progression to DCM and HF following myocarditis. 
4. Conclusions 
Biomarkers are an important clinical tool for assessing progression to heart failure. DCM 
often leads to HF, and myocarditis is an important cause of acute (sudden death) and 
chronic (arising from DCM) forms of HF. Even though myocarditis is known to be an 
important cause of HF, few clinical studies have been conducted to determine the presence 
or usefulness of HF biomarkers in predicting adverse outcomes in myocarditis patients. 
Studies that have been conducted in myocarditis/DCM patients or animal models suggest 
that many of the biomarkers used to assess the likelihood of progression to heart failure in 
other CVDs will also provide useful information in myocarditis/DCM patients. More 
studies examining the ability of circulating HF biomarkers to predict poor outcome and HF 
in animal models of myocarditis/DCM are needed. Animal models will also provide 
valuable information on the potential role of HF biomarkers in the pathogenesis of disease. 
This knowledge is critical in determining the ability of therapies targeted to these 
biomarkers to prevent disease progression. 
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